

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

NCT06605378

Status RECRUITING
Sponsor Ensoma
Enrollment 60 participants

Key Eligibility Criteria

Inclusion (3)

- The participant must have been diagnosed with CGD based on the referring physician's confirmation that NADPH oxidase activity is $\leq 5\%$ (i.e., the percentage of dihydrorhodamine-positive [DHR+] cells is $\leq 5\%$ by flow cytometry) OR based on confirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2, NCF4, or CYBC1).
- The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.
- The participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (ICF).

Exclusion (2)

- The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
- The participant is unable to comply with the sample collection procedure based on investigator judgment.

Locations (52 total)

Home-based telemedicine, Montgomery, Alabama, United States
Home-based telemedicine, Phoenix, Arizona, United States
Home-based telemedicine, Little Rock, Arkansas, United States
... and 49 more locations

<https://clinicaltrials.gov/study/NCT06605378>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.